ANVS Annovis Bio Inc

$ANVS After studying Buntanetap closely, the real differentiator is simple: it doesn't just chase surface symptoms or clean up downstream wreckage like failed legacy trials. It goes straight to the root cause upstream—acting as a ribosomal inhibitor to stop toxic protein overproduction at the source

$ANVS On Sept 2 Maria was asked, "Would Annovis Bio consider marketing the drug itself"? Rough answer: Yes. It is a simple calculation of return on investment. EXACTLY what I hoped to hear! Opinions follow: Imagine the ease of marketing a drug proven to impact the symptoms of Alzheimer's and modify the disease. Buntanetap is simple and inexpensive to manufacture, without significant side effects, shelf stable, a small oral pill, with enormous need & no real alternative. Most docs will know of the drug within days and want it for their patients suffering from various neuro degenerative diseases, not just AD. Marketing will be unlike other drugs as buntanetap is not a biologic with side effects needing Drug Reps to convince docs to prescribe. IF both P3s are successful, any company's market cap holding such an approved product will likely be measured in multiples of $10B and will have the ingredients necessary to become a dividend paying cash cow! 🙏↗️

$ANVS more reading on NFL protein if interested. The number of patients with NFL response when they phase 3 data is released, is much higher than all other studies combined. There will be a great deal of interest in these NFL levels. Not just to approve the drug. It will validate the value of using NFL protein as a surrogate marker for clinical response and disease modification. It will change the way FDA evaluate drugs for approval. Improvement in NFL protein levels is the path for early FDA approval. The stock price tomorrow has nothing to do with what it will be in a year. The reason for this is a few possibilities. However, the most likely response is the value of computer program trading across multiple hedge funds. A lot of these trades have six digits after the decimal point. I am sure this is not amusing to many. However, it is a once in a lifetime opportunity to make a huge amount of money. Study the science. It is not difficult to understand how this ends in my opinion.

$ANVS Where things stand now The ongoing Phase 3 Alzheimer's trial has completed enrollment with 862 biomarker-confirmed patients, exceeding the original enrollment target. A safety review by an independent monitoring board found no safety concerns and recommended the trial continue without changes. According to the company, top-line Phase 3 symptomatic efficacy data are expected after database lock and analysis, with results planned for release in 2027. Bottom line: The early results are encouraging because buntanetap showed cognitive improvement in a subgroup of Alzheimer's patients and reduced several disease-related biomarkers while appearing safe. However, it remains an investigational drug, and the ongoing Phase 3 trial must confirm these benefits before it can be considered for FDA approval.

$ANVS It never ceases to amaze me how many "experts" pop out of the woodwork (it's an old saying 😂) when a stock is beat to hell by short sellers, hedge funds, algorithmic trading, etc. "Oh, the CEO should have done this and that and the other thing cause I know so much more than they, and everything they do is a mistake!" Blah, blah, blah... Micro bios are major event driven. ANVS is not to blame that roughly every company attempting greatness in the dementia space has failed, and it is assumed they will fail, too! The MoA here is unique, appears to work in confirmed AD patients, and makes complete sense. From current levels, IF the results of the P3 symptomatic trail are positive and announced in mid-March, the gains will be enormous! And if the same is true the following March (2028) for AD disease modification, the likelihood of a multi-$100 stock is very real! It's not my call if the risk is suited for you, but I'm still accumulating...

$ANVS Both presentations I am believing are the ones she needs to be with for the financing and to push this over. They will have an inclination on the update/results from yours truly maria stugatz

$ANVS I am in Parkinsons OLE. Coming up on 6 months. I feel great. Doing more. Better attitude. Thank you, Maria, and Annovis team.

$ANVS Probably not bad pricing. 2029 $2.50 calls $5.00 or $500 2028 $2.50 calls $4.00 or $400 2027 $2.50 calls $3.00 or $300 Eventually the prices will adjust for a binary event Congrats on the .20, .25, 2029 call prices

$ANVS im in open label PD trial. over 6 months. my hands and feet are warm, used to be cold. Are the autonomic nerves repairing?

$ANVS I bought another 100,000 shares this week. I will do the same next week. IMO, outcome is known. I hope to have a million shares before it breaks 1.40. I am close already. What retail does will not impact how much money I make. The people involved in this share price manipulation are bad people. IMO, it deserves a criminal investigation. Meanwhile, don’t just take it. You will never get another chance like this. Again, my opinion, but buy what you can afford.

$ANVS This is ANVS data. Clinical response from Buntanetap seems far superior to generics. No competition here. Everyone will take Buntanetap based on this clinal response

$ANVS I've set up $25 a day recurring buy on this till results in April. It's definitely not the dumbest thing I ever did, but could yet be the smartest thing I ever did.

$ANVS I made some good $ on this ticker back in April/May 2024. Kinda forgot about til today. I was scrolling and saw the price…did some quick research and bought 12,000 shares. With some good news(especially in March) this could easily 10X. I bought SLS, IBRX and DRTS last year and I believe by next Summer this could easily duplicate their success. I’m 100% sure I’ll get my initial investment back. Gnna buy some more if it keeps going down. Time will tell, but I’m excited to see what happens!!!

$ANVS LOL still a bull. My last post was a pocket-post. Not worried about a reverse split. I’m holding for readout and accumulating today.

$ANVS Reminder of ANVS Biomarker data. Also, yes it is disease modification. It has been awhile since this phase 3 trial was designed. Between that time and now understanding of these Biomarkers has exploded. Big Pharma spent Billions of dollars to try to make the “Amyloid deposits” disappear. That seemed reasonable, but it was not the solution.

$ANVS It seems that many are assuming that buntanetap is more than likely to reach statistical significance on cognition but not function based on the 3 month trial. But I think that making projections based on the phase 2 subgroup analysis, and not the general trends of placebo at 6 months, is a mistake. According to AI: Mild AD at 6 months Amyloid + p-Tau Positive are expected to: ~1.8 to 2.5 points drop Because the Phase 3 trial is large (N850) and biomarker-enriched for p-tau217, Annovis does not need a massive absolute score jump. Proving a relative separation of ~1.0 point on ADCS-iADL will clear the statistical bar (p<0.05) for its 6-month symptomatic functional primary endpoint. So if placebo behaves as expected, buntanetap must only stabilize or less . With improving cog, lower tau, and NfL, is this not likely?

$ANVS I feel like it's time for another reminder of the promising preliminary results here that suggest the ongoing Alzheimer's phase 3 will work. Both these charts are for the subgroup of mild dementia patients who test positive for "amyloid" (really, p-tau). Those are the patients who were recruited to the current Alz phase 3. On the left is 3-month ADAS-Cog results from the phase 2 Alz trial; on the right is 6-month MMSE results from the phase 3 Parkinson's trial:

$ANVS Those companies will be like.... how is a phase 3 Alzheimers data play not worth 2.5 Billion minimum in market cap

$ANVS Folks, if AriBio meets primary endpoints in its Phase 3 POLARIS-AD trial, it could act as a massive macro catalyst for Annovis. It would offer direct proof-of-concept that an oral small molecule can be disease-modifying in Alzheimer’s, helping restore the sector-wide confidence lost after Cassava. Our biggest external catalyst this fall might just be a Korean drug readout!

$ANVS In biotech, you don't chase noise; you study the science, secure your entry, and wait like a sniper for the catalyst to strike.